Skip to main content
. 2020 Jan 10;18:2. doi: 10.1186/s12969-020-0399-1

Table 3.

Application of 2016 MAS classification criteria to patients with MAS treated with tocilizumab

Tocilizumab Historic cohort
Full-blown Possible All Full-blown Possible All
Number with sufficient data 2 10 12 10 8 18
MAS (%, n) 50 (1/2) 20 (2/10) 25 (3/12) 90 (9/10) 75 (6/8) 83 (15/18)
Reasons missing (n) Afebrile [1] Afebrile [4] Afebrile [1] Other markers [2]
Ferritin [5]

MAS Macrophage activation syndrome